![](/wp-content/uploads/2022/05/May-13-2022-Blast-Cover.png)
$599
Movano and Embecta Q1 ’22 Earnings Updates; Hygieia Launches d-Nav Clinical Partnership Program in Michigan
Three cardiometabolic-related news items have been observed: Movano (press release) and Embecta (press release; slides) hosted their respective Q1 ‘22 earnings calls; and Hygieia announced the launch of its d-Nav Clinical Partnership Program for endocrinology practices treating patients with T2DM. Below, FENIX provides highlights and insights for the respective new items.